CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gwo Xi Stem Cell Applied Technlgy Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gwo Xi Stem Cell Applied Technlgy Co Ltd
8 Lou
Guang Ming Liu Lu Dong Yi Duan 243 Hao
Phone: +886 36585959p:+886 36585959 ZHUBEI, 302  Taiwan Ticker: 67046704
Business Summary
Gwo Xi Stem Cell Applied Technology Co Ltd is a Taiwan-based company mainly engaged in the development of stem cell drugs and technologies for the treatment of refractory diseases. The Company owns the Medical-Grade Cell Preparation Platform for the collection, isolation, culture, scaling up, packaging, testing, transportation, storage and treatment of human stem cells. The platform is modularized to create the stem cell activation technology Nigiro-Med, medical grade stem cell storage service and clinical cell preparation quality testing service. The Company operates through Stem Cell Freezing segment, Health Care Products and Maintenance Products segment, and Other segment.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8071 Medical laboratories
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board MingxiZhuang 6/19/2024 3/22/2016
General Manager ChunfenQiu 6/19/2024
Independent Director ZhenjiangChen
Independent Director RongzhenLuo

General Information
Outstanding Shares: 95,949,000 (As of 6/30/2024)
Shareholders: 3,957
Stock Exchange: TPO
Fax Number: +886 36579922


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024